Farxiga (generic name: dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Farxiga acts as a blocker for the SGLT2 protein, which is situated in the early parts of the kidney tubules. Its primary function is to reabsorb the glucose from the filtered liquid back into the body. By doing this, the drug ensures that more glucose is expelled through urine rather than being taken back into the blood.
Beyond its effect on glucose, Farxiga also impacts how the kidneys handle salt. This can lead to several physiological effects, including reducing the workload on the heart, moderating specific body signals, and potentially decreasing the internal pressure within the kidney’s filtering units.
Outcomes include:

An improvement in glycemic control in adults with type 2 Diabetes
A reduction in the risk of sustained kidney decline
A reduction in the risk of hospitalization for heart failure in adults with diabetes or kidney decline

Dosage
Dosage is dependent on the underlying condition. It is essential to follow the prescribing healthcare professional’s instructions and read the Patient Information leaflet that comes with the package.

Some side effects are reported in the Patient Information leaflet.

• Vaginal yeast infections in women who experience vaginal odor, white or yellowish vaginal discharge, or vaginal itching.
• Yeast infection of the skin around the penis (balanitis)
• Nasopharyngitis
• Urinary tract infections.

If these do not clear up in a few days, or worsen, consult with a physician or pharmacist.

Failure to read and follow the information on the manufacturer’s Product Insert leaflet that comes with the medication can carry serious health risks. Please be aware that not all possible side effects can be listed here. If you experience any of these or any other unexpected side effects, consult with a healthcare provider immediately.